A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2023-09-12
Adverse events
Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-24 (study day 29); relationship: not assessed; serious criteria: life-threatening
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-12-27 (study day 93); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-01-28 (study day 125); relationship: not assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-02-05 (study day 133); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-03-23 (study day 180); relationship: not assessed
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-04-02 (study day 190); relationship: N
Data queries
No data queries.